Literature DB >> 10589371

Treatment of ocular infections with topical antibacterials.

J P Leeming1.   

Abstract

Topically applied ophthalmic antibacterial preparations are widely used in the treatment of patients with superficial ocular infections. In addition, they are frequently used to augment treatment for intraocular infection administered systemically or via local instillation. Direct application delivers high concentrations of antimicrobial agents to the surface of the eye conveniently, quickly and with minimal systemic exposure to the agent. However, antibacterials are rapidly dissipated from the tear film and intraocular penetration of topical antibacterial agents is generally poor, necessitating intensive application for successful treatment of corneal infections. Therapeutic concentrations are rarely achieved at other sites in the eye. This article reviews what is known of the pharmacokinetics of topical ocular agents and how this information can be used to optimise ocular persistence and penetration and minimise systemic absorption of antibacterials. A review of the features of the most commonly employed topical antibacterials suggests that for the treatment of uncomplicated bacterial conjunctivitis there is little difference between the various agents in terms of clinical efficacy, although chloram-phenicol should be used with care because of its potential haematological toxicity. Carefully considered therapy is imperative for bacterial keratitis; fortified beta-lactam/aminoglycoside combinations are often used for these infections. The fluoroquinolones appear promising, but caution is necessary in treating keratitis of unknown aetiology with these agents alone because of inherent and emerging acquired resistance among Gram-positive bacteria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589371     DOI: 10.2165/00003088-199937050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  59 in total

1.  Ocular penetration of topically applied gentamicin.

Authors:  B Ellerhost; B Golden; N Jarudi
Journal:  Arch Ophthalmol       Date:  1975-05

2.  Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis.

Authors:  H M Leibowitz
Journal:  Am J Ophthalmol       Date:  1991-10       Impact factor: 5.258

3.  Concentration of gentamicin in experimental corneal ulcers. Topical vs subconjunctival therapy.

Authors:  J L Baum; M Barza; D Shushan; L Weinstein
Journal:  Arch Ophthalmol       Date:  1974-10

4.  Loading doses and extended dosing intervals in topical gentamicin therapy.

Authors:  D B Glasser; S Gardner; J G Ellis; T H Pettit
Journal:  Am J Ophthalmol       Date:  1985-03-15       Impact factor: 5.258

5.  Fusidic acid in acute conjunctivitis. Single-blind, randomized comparison of fusidic acid and chloramphenicol viscous eye drops.

Authors:  J Hvidberg
Journal:  Acta Ophthalmol (Copenh)       Date:  1987-02

6.  Human conjunctivitis. I. Diagnostic evaluation.

Authors:  H W Leibowitz; M V Pratt; I J Flagstad; A R Berrospi; R Kundsin
Journal:  Arch Ophthalmol       Date:  1976-10

7.  Iontophoresis of gentamicin into aphakic rabbit eyes. Sustained vitreal levels.

Authors:  P H Fishman; W M Jay; J P Rissing; J M Hill; R K Shockley
Journal:  Invest Ophthalmol Vis Sci       Date:  1984-03       Impact factor: 4.799

8.  Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis.

Authors:  D J Parks; D A Abrams; F A Sarfarazi; H R Katz
Journal:  Am J Ophthalmol       Date:  1993-04-15       Impact factor: 5.258

9.  Topical tobramycin therapy of experimental Pseudomonas keratitis: an evaluation of some factors that potentially enhance efficacy.

Authors:  S D Davis; L D Sarff; R A Hyndiuk
Journal:  Arch Ophthalmol       Date:  1978-01

10.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

View more
  10 in total

1.  Topical ocular antibiotics induce bacterial resistance at extraocular sites.

Authors:  B D Gaynor; J D Chidambaram; V Cevallos; Y Miao; K Miller; H C Jha; R C Bhatta; J S P Chaudhary; S Osaki Holm; J P Whitcher; K A Holbrook; A M Fry; T M Lietman
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials.

Authors:  Rahul Garhwal; Sally F Shady; Edward J Ellis; Jeanne Y Ellis; Charles D Leahy; Stephen P McCarthy; Kathryn S Crawford; Peter Gaines
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-13       Impact factor: 4.799

Review 3.  Corneal ulceration in pediatric patients: a brief overview of progress in topical treatment.

Authors:  Serina Stretton; Usha Gopinathan; Mark D P Willcox
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

4.  Label-free electrical sensing of bacteria in eye wash samples: A step towards point-of-care detection of pathogens in patients with infectious keratitis.

Authors:  Hardik J Pandya; Manoj Kumar Kanakasabapathy; Saloni Verma; Manjyot Kaur Chug; Adnan Memic; Mihaela Gadjeva; Hadi Shafiee
Journal:  Biosens Bioelectron       Date:  2016-12-13       Impact factor: 10.618

5.  Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops.

Authors:  Mahendra Singh Rathore; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-07-07       Impact factor: 3.246

Review 6.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

7.  Transcorneal permeation of ciprofloxacin and diclofenac from marketed eye drops.

Authors:  N Patidar; M S Rathore; D K Sharma; A Middha; V B Gupta
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

8.  Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis.

Authors:  S Khimdas; K L Visscher; C M L Hutnik
Journal:  Ophthalmol Eye Dis       Date:  2011-03-20

9.  A European perspective on topical ophthalmic antibiotics: current and evolving options.

Authors:  D Bremond-Gignac; F Chiambaretta; S Milazzo
Journal:  Ophthalmol Eye Dis       Date:  2011-10-24

Review 10.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.